Long pages

Jump to navigation Jump to search

Showing below up to 50 results in range #51,001 to #51,050.

View ( | ) (20 | 50 | 100 | 250 | 500)

  1. (hist) Thoughts On Sand Casting Parts In Simple Step By Step Order [3,832 bytes]
  2. (hist) ZNF133 [3,832 bytes]
  3. (hist) PIGN (gene) [3,832 bytes]
  4. (hist) IMITREX injection clinical studies [3,832 bytes]
  5. (hist) WBR0209 [3,832 bytes]
  6. (hist) WBR0199 [3,832 bytes]
  7. (hist) Lymphadenopathy (patient information) [3,832 bytes]
  8. (hist) SLC7A2 [3,832 bytes]
  9. (hist) Acacia rigidula [3,832 bytes]
  10. (hist) Laryngeal prominence [3,832 bytes]
  11. (hist) Spatial dependence [3,832 bytes]
  12. (hist) Psychogenic disease [3,832 bytes]
  13. (hist) Oxeye daisy [3,832 bytes]
  14. (hist) Duct (anatomy) [3,832 bytes]
  15. (hist) Galanin-like peptide [3,831 bytes]
  16. (hist) Brucellosis primary prevention [3,831 bytes]
  17. (hist) Metatarsalphalangeal joint sprain [3,831 bytes]
  18. (hist) Rigshospitalet [3,831 bytes]
  19. (hist) Royan Institute [3,831 bytes]
  20. (hist) ZNF331 [3,830 bytes]
  21. (hist) SPOCK2 [3,830 bytes]
  22. (hist) Direct Xa inhibitor [3,830 bytes]
  23. (hist) WBR0800 [3,830 bytes]
  24. (hist) Menopause historical perspective [3,830 bytes]
  25. (hist) OR7C1 [3,830 bytes]
  26. (hist) Prometaphase [3,830 bytes]
  27. (hist) MRGPRX2 [3,830 bytes]
  28. (hist) Gaussian process [3,830 bytes]
  29. (hist) Dictamnus [3,830 bytes]
  30. (hist) Calcium tartrate [3,830 bytes]
  31. (hist) Ruthenocene [3,830 bytes]
  32. (hist) Salicylaldoxime [3,830 bytes]
  33. (hist) Interatrial septum [3,830 bytes]
  34. (hist) Paclitaxel (patient information) [3,830 bytes]
  35. (hist) Sexcord/ stromal ovarian tumors risk factors [3,829 bytes]
  36. (hist) MAP3K9 [3,829 bytes]
  37. (hist) FAM155A [3,829 bytes]
  38. (hist) Infectious colitis epidemiology and demographics [3,829 bytes]
  39. (hist) The Negative Predictive Value of D-dimer on the Risk of Recurrent Venous Thromboembolism in Patients With Multiple Previous Events: a Prospective Cohort Study [3,829 bytes]
  40. (hist) Upper gastrointestinal bleeding primary prevention [3,829 bytes]
  41. (hist) Esophageal cancer history and symptoms [3,829 bytes]
  42. (hist) The Living Guidelines: UA/NSTEMI Recommendations for Anti Ischemic Therapy Suggest Revisions to the CLASS IIb Guidelines [3,829 bytes]
  43. (hist) The Living Guidelines: Antiplatelet Agents/Anticoagulants: Warfarin View the Current CLASS I Guidelines [3,829 bytes]
  44. (hist) The Living Guidelines: PCI after Successful Fibrinolysis or for Patients Not Undergoing Primary Reperfusion Suggest Revisions to the CLASS I Guidelines [3,829 bytes]
  45. (hist) Mediastinum [3,829 bytes]
  46. (hist) M-Toluic acid [3,829 bytes]
  47. (hist) Penicillin G potassium microbiology [3,828 bytes]
  48. (hist) Creutzfeldt-Jakob disease future or investigational therapies [3,828 bytes]
  49. (hist) Parotitis causes [3,828 bytes]
  50. (hist) Obsessive-compulsive disorder other imaging findings [3,828 bytes]

View ( | ) (20 | 50 | 100 | 250 | 500)